FDA Adverse Event Malfunction Summary report: N

ACCU-CHEK SPIRIT CARTRIDGE

MDR report key: 3010413 · Received March 19, 2013

Report

Report Number
2183996-2013-00402
Event Type
Malfunction
Date Received
March 19, 2013
Date of Event
March 7, 2013
Report Date
May 10, 2013
Manufacturer
ROCHE DIABETES CARE AG
Product Code
LZG
PMA / PMN Number
NA
Removal / Correction Number
NA
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
GM
Reporter Occupation
MEDICAL EQUIPMENT COMPANY TECHNICIAN/REPRESENTATIVE

Narratives

Additional Manufacturer Narrative · 1

THE COMPLAINT CANNOT BE VERIFIED. THE MATERIAL MEETS PRODUCT SPECIFICATIONS. THE TWO USED AND FOURTEEN UNUSED CARTRIDGES WERE VISUALLY, LEAK AND GLIDE FORCE TESTED. THE CARTRIDGES PASSED THE VISUAL TEST AND THE LEAKAGE TEST AT DIFFERENT POSITIONS OF THE PLUNGER ROD. THE GLIDE FORCE MEASURED IS IN ACCORDANCE WITH PRODUCT SPECIFICATIONS. THE TWO USED RETURNED TRANSFER SETS WERE VISUALLY INSPECTED AND TESTED FOR FLOW AND TIGHTNESS. BOTH TRANSFER SETS WERE OCCLUDED WITH INSULIN BEHIND THE CONNECTOR NEEDLE. THE MANUFACTURER TESTS ALL PRODUCTS DURING PRODUCTION FOR LEAK AND FLOW; THEREFORE, THERE IS NO INDICATION THAT A NONSPECIFIC PRODUCT WAS DELIVERED TO THE CUSTOMER. THE ADAPTER PASSED THE OPTICAL INSPECTION.

Additional Manufacturer Narrative · 1

THE INCIDENT OCCURRED OUTSIDE THE UNITED STATES. INFORMATION CONTAINED WITHIN THIS REPORT IS ALL THAT IS AVAILABLE AT THIS TIME. IF FURTHER INFORMATION IS OBTAINED, IT WILL BE PROVIDED IN THE SUPPLEMENTAL REPORT.

Description of Event or Problem · 1

PATIENT REPORTED THE CARTRIDGES HAVE LEAKED INSULIN NEAR THE ADAPTER. NO PHYSIOLOGICAL EFFECTS WERE REPORTED, AND SHE DID NOT REQUIRE TREATMENT FROM A HEALTHCARE PROFESSIONAL OR SECOND PARTY TO ADDRESS THE ISSUE. THE CARTRIDGES WERE REQUESTED FOR EVALUATION.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
114620 ACCU-CHEK SPIRIT CARTRIDGE INSULIN INFUSION PUMP CARTRIDGE LZG ROCHE DIABETES CARE AG 00700006871 32392262

Patients

Seq Age Sex Outcome Treatment
1 055 YR